目的探析日常生活能力评定量表在精神科病房分级护理管理中的应用效果。方法选取我院精神科病房178例患者作为研究对象,随机分为观察组与对照组各89例;其中对照组由护理人员遵照医生开具的护理级别医嘱进行护理,观察组由护理人员通过观...目的探析日常生活能力评定量表在精神科病房分级护理管理中的应用效果。方法选取我院精神科病房178例患者作为研究对象,随机分为观察组与对照组各89例;其中对照组由护理人员遵照医生开具的护理级别医嘱进行护理,观察组由护理人员通过观察患者病情,参照日常生活能力评定量表(Activity of daily living scale,ADL)制定护理分级从而进行护理。比较分析两组患者的基础护理质量(皮肤与口腔卫生、衣着卫生、饮食护理、排泄护理、睡眠护理)、护理满意度以及住院期间不良事件发生率。结果观察组的皮肤与口腔卫生、衣着卫生、饮食护理、排泄护理、睡眠护理评分均显著高于对照组(均P<0.001);观察组的护理满意度为96.6%,显著高于对照组85.4%(P<0.001);观察组的不良事件发生率为7.9%,显著低于对照组20.2%(P=0.033)。结论通过结合ADL确定精神科病房患者的护理分级可有效提高基础护理质量、护理满意度,并有效减少患者住院期间的不良事件发生率,同时增加患者的依从性,具有良好的临床实用价值。展开更多
Chiglitazar(Carfloglitazar)is a novel peroxisome proliferator-activated receptor(PPAR)pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes.In this rand...Chiglitazar(Carfloglitazar)is a novel peroxisome proliferator-activated receptor(PPAR)pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes.In this randomized phase 3 trial,we compared the efficacy and safety of chiglitazar with sitagliptin in patients with type 2 diabetes who had insufficient glycemic control despite a strict diet and exercise regimen.Eligible patients were randomized(1:1:1)to receive chiglitazar 32 mg(n=245),chiglitazar 48 mg(n=246),or sitagliptin 100 mg(n=248)once daily for 24 weeks.The primary endpoint was the change in glycosylated hemoglobin A_(1C)(HbA_(1c))from baseline at week 24 with the non-inferiority of chiglitazar over sitagliptin.Both chiglitazar and sitagliptin significantly reduced HbA1c at week 24 with values of-1.40%,-1.47%,and-1.39%for chiglitazar 32 mg,chiglitazar 48 mg,and sitagliptin 100 mg,respectively.Chiglitazar 32 and 48 mg were both non-inferior to sitagliptin 100 mg,with mean differences of-0.04%(95%confidential interval(Cl)-0.22 to 0.15)and-0.08%(95%Cl-0.27 to 0.10),respectively.Compared with sitagliptin,greater reduction in fasting and 2-h postprandial plasma glucose and fasting insulin was observed with chiglitazar.Overall adverse event rates were similar between the groups.A small increase in mild edema in the chiglitazar 48 mg group and slight weight gain in both chiglitazar groups were reported.The overall results demonstrated that chiglitazar possesses good efficacy and safety profile in patients with type 2 diabetes inadequately controlled with lifestyle interventions,thereby providing adequate supporting evidence for using this PPAR pan-agonist as a treatment option for type 2 diabetes.展开更多
文摘目的探析日常生活能力评定量表在精神科病房分级护理管理中的应用效果。方法选取我院精神科病房178例患者作为研究对象,随机分为观察组与对照组各89例;其中对照组由护理人员遵照医生开具的护理级别医嘱进行护理,观察组由护理人员通过观察患者病情,参照日常生活能力评定量表(Activity of daily living scale,ADL)制定护理分级从而进行护理。比较分析两组患者的基础护理质量(皮肤与口腔卫生、衣着卫生、饮食护理、排泄护理、睡眠护理)、护理满意度以及住院期间不良事件发生率。结果观察组的皮肤与口腔卫生、衣着卫生、饮食护理、排泄护理、睡眠护理评分均显著高于对照组(均P<0.001);观察组的护理满意度为96.6%,显著高于对照组85.4%(P<0.001);观察组的不良事件发生率为7.9%,显著低于对照组20.2%(P=0.033)。结论通过结合ADL确定精神科病房患者的护理分级可有效提高基础护理质量、护理满意度,并有效减少患者住院期间的不良事件发生率,同时增加患者的依从性,具有良好的临床实用价值。
基金the Chinese National and Provincial Major Project for New Drug Innovation(National:2008ZX09101-002,2013ZX09401301Provincial:2011A080501010)Shenzhen Municipal Major Project(2010-1746)。
文摘Chiglitazar(Carfloglitazar)is a novel peroxisome proliferator-activated receptor(PPAR)pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes.In this randomized phase 3 trial,we compared the efficacy and safety of chiglitazar with sitagliptin in patients with type 2 diabetes who had insufficient glycemic control despite a strict diet and exercise regimen.Eligible patients were randomized(1:1:1)to receive chiglitazar 32 mg(n=245),chiglitazar 48 mg(n=246),or sitagliptin 100 mg(n=248)once daily for 24 weeks.The primary endpoint was the change in glycosylated hemoglobin A_(1C)(HbA_(1c))from baseline at week 24 with the non-inferiority of chiglitazar over sitagliptin.Both chiglitazar and sitagliptin significantly reduced HbA1c at week 24 with values of-1.40%,-1.47%,and-1.39%for chiglitazar 32 mg,chiglitazar 48 mg,and sitagliptin 100 mg,respectively.Chiglitazar 32 and 48 mg were both non-inferior to sitagliptin 100 mg,with mean differences of-0.04%(95%confidential interval(Cl)-0.22 to 0.15)and-0.08%(95%Cl-0.27 to 0.10),respectively.Compared with sitagliptin,greater reduction in fasting and 2-h postprandial plasma glucose and fasting insulin was observed with chiglitazar.Overall adverse event rates were similar between the groups.A small increase in mild edema in the chiglitazar 48 mg group and slight weight gain in both chiglitazar groups were reported.The overall results demonstrated that chiglitazar possesses good efficacy and safety profile in patients with type 2 diabetes inadequately controlled with lifestyle interventions,thereby providing adequate supporting evidence for using this PPAR pan-agonist as a treatment option for type 2 diabetes.
